b-Net income The company said the magnitude of the loss reflects the writeoff of $1,850,000 prepaid drug licensing fees acquired in November 1986; a $988,000 decrease in the carrying value of the company's investment in International Surgical and Pharmaceutical Corp. to its estimated realizable value; a $750,000 increase in the reserve against Medicare receivables; a $350,000 writeoff of goodwill and formulations acquired in connection with the purchase of the assets of Generic Blends & Chemical Corp. in May 1986; costs associated with the withdrawal of the proposed initial public offering of A.N.D.A. Development Corp. as well as the traditionally slow summer season for Generic OTC Pharmaceuticals.